Jinwon Life Sciences Obtains Approval for Subsidiary VGXI's New Factory Occupancy
[Asia Economy Reporter Jang Hyowon] Genwin Life Sciences announced on the 21st that its subsidiary VGXI, a plasmid DNA contract development and manufacturing organization (CDMO), has received occupancy approval after the completion inspection of a new factory built in Deison Technology Park, Conroe City, Texas, USA.
The company explained, "The inspection was conducted according to Conroe's strict safety diagnosis and fire inspection procedures for facilities, and with the acquisition of occupancy approval, we will move in as soon as possible to commence commercial production of high-quality plasmid DNA."
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Park Younggeun, CEO of Genwin Life Sciences, stated, "The new factory is a large-scale plasmid DNA production facility with differentiated quality that can meet the demand for DNA and RNA pharmaceuticals based on VGXI's accumulated expertise. It is also capable of producing mRNA bulk, establishing itself as an advanced facility that can satisfy the diverse needs of our clients."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
